Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 9237481, 6 pages
Research Article

Association of ABO Blood Types and Clinicopathological Features of Prostate Cancer

1Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China
2Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Bei Li Shi Road 167, Beijing 100037, China

Correspondence should be addressed to Fang-Ming Wang; moc.361@gnimgnafiygniq, Li-Jiang Sun; moc.621@999gnaijils, and Yong Liu; moc.361@yuilyfyq

Received 23 July 2017; Revised 19 August 2017; Accepted 6 September 2017; Published 9 October 2017

Academic Editor: Michele Malaguarnera

Copyright © 2017 Fang-Ming Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To investigate the association between ABO blood types and clinicopathological characteristics in patients with prostate cancer (PC). Methods. A total of 237 pathologically diagnosed PC patients were enrolled. All patients were classified as low–middle or high-risk group. The correlation of ABO blood types with high-risk PC was determined by univariate and multivariate regression analysis. Results. Data indicated 144 (85.7%) patients were stratified as high risk in the non-O group, while 50 (72.5%) patients in the O group (). However, there was no significant difference regarding PSA, Gleason score, stage, or metastasis between O and non-O group (). Univariate logistic regression analyses revealed PSA, Gleason score, and blood type non-O were all correlated with high-risk PC (OR = 1.139, ; OR = 9.465, ; OR = 2.280, , resp.). In the stepwise multivariate regression analysis, the association between blood type non-O and high-risk PC remained significant (OR = 33.066, 95% CI 2.391–457.323, and ) after adjusting for confounding factors as well as PSA and Gleason score. Conclusion. The present study firstly demonstrated that non-O blood type was at higher risk of aggressive PC compared with O type, suggesting that PC patients with non-O blood type should receive more attention in clinical practice.